Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
EBIATOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Allarity Therapeutics (ALLR) Shares Outstanding (2024 - 2025)

Allarity Therapeutics' Shares Outstanding history spans 2 years, with the latest figure at $19.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 160.59% year-over-year to $19.0 million; the TTM value through Dec 2025 reached $19.0 million, up 160.59%, while the annual FY2025 figure was $19.0 million, 160.59% up from the prior year.
  • Shares Outstanding reached $19.0 million in Q4 2025 per ALLR's latest filing, up from $18.7 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $19.0 million in Q4 2025 to a low of $7.3 million in Q4 2024.